Peptides for Leaky Gut: BPC-157, LL-37, and Tight Junction Repair

Intestinal permeability — colloquially called leaky gut — is a condition in which the tight junctions between intestinal epithelial cells become compromised, allowing bacterial fragments, undigested food proteins, and toxins to enter the bloodstream. The result is systemic inflammation that has been linked to autoimmune disease, mood disorders, metabolic dysfunction, and chronic fatigue.

Conventional treatment focuses on dietary elimination, prebiotics, and probiotics. Peptide therapy represents an emerging and mechanistically compelling adjunct, with BPC-157 and LL-37 showing the most evidence for directly repairing intestinal barrier function.

What Is Leaky Gut and Why Does It Matter

The intestinal epithelium is a single layer of cells linked by protein complexes called tight junctions. These junctions — composed of occludin, claudin, and zonulin-regulated proteins — act as selective gatekeepers. When they function correctly, nutrients pass through while pathogens and large molecules are blocked.

When tight junctions open excessively, a process driven by zonulin (a protein that modulates tight junction permeability), inflammatory cytokines, dysbiotic bacteria, gluten, alcohol, and NSAIDs, the barrier fails. Lipopolysaccharide (LPS) from gram-negative bacteria enters the portal circulation, triggering systemic endotoxemia. Even low-grade chronic endotoxemia drives insulin resistance, neuroinflammation, and elevated CRP.

Repairing intestinal permeability requires more than removing triggers — it requires active repair of the epithelial barrier and restoration of tight junction protein expression.

BPC-157: The Core Peptide for Gut Barrier Repair

BPC-157 (Body Protection Compound 157) is a 15-amino acid peptide derived from a sequence found in human gastric juice. It was originally identified for its cytoprotective effects in the stomach, and decades of animal research have expanded the picture considerably.

Tight junction restoration: BPC-157 upregulates expression of tight junction proteins including claudin-1, occludin, and ZO-1. In animal models of colitis and intestinal permeability, BPC-157 significantly reduced mucosal damage and restored barrier function measurably faster than controls.

Anti-inflammatory effects: By modulating the nitric oxide system and downregulating pro-inflammatory cytokines (TNF-α, IL-6), BPC-157 reduces the inflammatory environment that perpetuates leaky gut. It appears to modulate NF-κB signaling, a central driver of gut inflammation.

Angiogenesis and mucosal healing: BPC-157 stimulates VEGF-driven angiogenesis in the gut mucosa, improving blood supply to damaged tissue and accelerating epithelial regeneration. This mechanism is well-supported in models of NSAID-induced gut damage, short bowel syndrome, and anastomotic healing.

Zonulin pathway: Animal data suggests BPC-157 may attenuate zonulin-mediated tight junction opening, though human data on this specific pathway is still emerging.

See the full profile at BPC-157 Peptide Guide and Peptides for Gut Healing.

LL-37: Antimicrobial Peptide for Dysbiosis and Barrier Function

LL-37 is a human cathelicidin — a class of antimicrobial peptide produced by immune cells and epithelial cells throughout the body, including the gut. It serves dual roles: direct antimicrobial activity and immunomodulation.

Antimicrobial action: LL-37 disrupts bacterial membranes of both gram-positive and gram-negative bacteria, including many dysbiotic species linked to leaky gut. Critically, it targets pathogenic bacteria while being less destructive to commensal organisms at physiological concentrations.

Tight junction support: Beyond killing pathogens, LL-37 directly influences epithelial barrier function. It activates EGF receptor (EGFR) signaling in intestinal epithelial cells, promoting barrier repair and reducing apoptosis. In inflammatory bowel models, LL-37 reduces intestinal permeability and promotes mucosal healing.

Immune modulation: LL-37 has a complex immune role — it is pro-inflammatory in some contexts and anti-inflammatory in others, depending on concentration and tissue environment. In the gut, its net effect appears to be resolution of pathological inflammation while maintaining innate immune competence.

For background on LL-37's broader immune roles, see LL-37 Peptide Guide.

The Zonulin Pathway and Peptide Intervention

Zonulin is the primary physiological regulator of tight junctions. Elevated zonulin — found in celiac disease, IBS, and non-celiac gluten sensitivity — predicts intestinal permeability and correlates with systemic inflammation markers.

Triggers that upregulate zonulin include:

• Dietary gluten (via CXCR3 receptor activation in the gut)
• Small intestinal bacterial overgrowth (SIBO)
• Lipopolysaccharide exposure
• High-fat, high-sugar diets

Peptide interventions that appear to counter excessive zonulin activity include BPC-157, which stabilizes tight junction complexes, and potentially glutamine-containing peptide sequences in hydrolyzed collagen, which provide substrate for intestinal epithelial repair.

Serum zonulin testing (via Actim Zonulin ELISA) gives a useful baseline for tracking barrier repair. Expect gradual normalization over 8–16 weeks of consistent protocol adherence.

Supporting Peptides and Adjuncts

Pentadecapeptide (Larazotide Acetate): A tight junction regulator that has shown clinical promise in celiac disease trials, reducing intestinal permeability measured by lactulose/mannitol ratio. See Pentadecapeptide Guide.

Collagen Peptides: Hydrolyzed collagen provides glycine, proline, and hydroxyproline — the structural amino acids for intestinal epithelial repair. While not directly targeting tight junctions, collagen peptides support the matrix that underlies the epithelium. Daily collagen supplementation (10–15 g) is a logical and low-risk foundation.

Thymosin Beta-4 (TB-500): TB-500 has anti-inflammatory properties and promotes tissue repair via actin cytoskeleton remodeling. Its potential in gut healing is less studied than BPC-157, but the anti-inflammatory mechanism is relevant in conditions like IBD.

A Practical Leaky Gut Protocol

Phase 1 — Remove triggers (weeks 1–4): Eliminate gluten, minimize alcohol and NSAIDs, address SIBO if confirmed via breath testing. Begin probiotics (Lactobacillus rhamnosus GG, Bifidobacterium longum) and dietary prebiotics.

Phase 2 — Active barrier repair (weeks 2–12):

• BPC-157: 250–500 mcg daily (oral or subcutaneous). Oral capsule form is convenient and delivers the peptide directly to the gut lumen. Subcutaneous allows systemic anti-inflammatory effects.
• Collagen peptides: 15 g daily with vitamin C
• Zinc carnosine: 75 mg twice daily (synergistic with BPC-157 for mucosal repair)
• L-glutamine: 5–10 g daily as substrate for enterocytes

Phase 3 — Consolidation and testing (weeks 12–20): Retest zonulin and lactulose/mannitol permeability. Continue lower-dose BPC-157 (250 mcg, 5 days/week) alongside dietary maintenance. Slowly reintroduce foods removed in Phase 1 one at a time.

Work with a gastroenterologist or functional medicine physician to confirm the diagnosis and rule out inflammatory bowel disease, which requires different management.

Frequently Asked Questions

Q: Should I take BPC-157 orally or as an injection for leaky gut?

For gut-specific permeability issues, oral BPC-157 (in capsule form) delivers the peptide directly to the intestinal lumen where it can act locally on tight junctions and mucosal tissue. Subcutaneous injection provides systemic anti-inflammatory effects. Many practitioners use oral dosing for gut-specific applications and reserve injection for broader systemic uses.

Q: How long does it take for peptides to repair leaky gut?

Improvements in tight junction protein expression have been documented within 2–4 weeks in animal studies. Human clinical experience suggests subjective improvement (reduced bloating, better tolerance, improved stool consistency) within 4–6 weeks, with measurable permeability normalization at 8–16 weeks depending on the severity of the initial damage and adherence to dietary changes.

Q: Can BPC-157 help with Crohn's disease or ulcerative colitis?

Animal models of IBD consistently show BPC-157 reducing mucosal inflammation, ulceration, and permeability. There are no large human RCTs in IBD as of 2026. Some clinicians use it as adjunctive therapy in IBD patients, but it should not replace established IBD treatments. Discuss with a gastroenterologist.

Q: Is LL-37 available as a supplement?

LL-37 is available as a research peptide for injection. It is not available as an oral supplement because it is degraded by digestive enzymes before reaching systemic circulation. Topical LL-37 is used in dermatology. For gut applications, systemic injectable LL-37 is the relevant form, though clinical evidence for this specific use in humans is still limited.

Q: What diet should accompany peptide therapy for leaky gut?

A whole-foods, anti-inflammatory diet with adequate fiber supports the microbiome changes necessary for sustained barrier repair. Remove confirmed triggers (gluten if you have positive antibodies, dairy if intolerant), maximize variety of plant foods for microbiome diversity, and ensure adequate zinc, vitamin D, and glutamine intake. Peptides work best as an accelerant on top of a solid dietary foundation — not as a replacement for it.